Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Human Immunodeficiency Virus Therapeutics Market?

The market for therapeutic treatments for the human immunodeficiency virus has seen a potent expansion in recent times. From $14.11 billion in 2024, the market is forecasted to augment to $14.94 billion in 2025, registering a compound annual growth rate (CAGR) of 5.8%. The robust growth during the historical period can be accredited to the rise in instances of HIV, an increase in awareness campaigns, a spike in diagnostic testing, an expansion in the infiltration of generic drugs, and an enhancement in healthcare infrastructure.

What Growth Rate Is Forecasted for the Human Immunodeficiency Virus Therapeutics Market by 2029?

The market size for therapeutics treating the human immunodeficiency virus is projected to exhibit substantial growth in the coming years. It is predicted to reach $18.57 billion by 2029, growing at a compound annual growth rate (CAGR) of 5.6%. The expansion during the projected period can be ascribed to a growing base of HIV patients, enhanced HIV screening, increasing voluntary testing, a rise in unprotected sex habits, and the enlargement of government initiatives. Notable advancements anticipated during this period encompass technological progression, AI-fueled drug invention, enduring injectable treatments, the inclusion of telemedicine, and gene therapy based on CRISPR.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23419&type=smp

Which Key Companies Are Shaping the Future of the Human Immunodeficiency Virus Therapeutics Market?

Major companies operating in the human immunodeficiency virus therapeutics market are Pfizer Inc., Johnson & Johnson, F Hoffmann La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi SA, Bristol Myers Squibb Company (BMS), Novartis International AG, GlaxoSmithKline plc (GSK), Gilead Sciences Inc., Moderna Inc., BioNTech SE, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Aurobindo Pharma Limited, Cipla Limited, Hetero Labs Limited, Gilead Sciences Inc. / Kite Pharma Inc. (for CAR T HIV cure research), Vir Biotechnology Inc., Theratechnologies Inc., CytoDyn Inc.

Which Factors Are Driving Demand in the Human Immunodeficiency Virus Therapeutics Industry?

The rise in unprotected sexual activities is anticipated to fuel the expansion of the human immunodeficiency virus therapeutics market. Unprotected sexual activities are those carried out without barrier protection, and these heighten the risk of contracting sexually transmitted infections (STIs) and unplanned pregnancies. Insufficient sex education, resulting in limited knowledge about safe practices, fosters risky behavior amongst younger individuals. These HIV therapeutics are designed to lower the possibility of HIV transmission due to unprotected sexual practices by reducing the viral load to levels that can no longer be detected, preventing further transmission. For instance, in November 2024, the Centers for Disease Control and Prevention, a US-based government agency, revealed in a 2023 survey that of all U.S. high school students, 32% admitted to having had sexual intercourse at least once, and 48% disclosed not having used a condom during their previous sexual encounter. As such, the rising prevalence of unprotected sexual practices serves as a significant factor driving the expansion of the human immunodeficiency virus therapeutics market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=23419&type=smp

How Is the Human Immunodeficiency Virus Therapeutics Market Segmented by Several Divisions?

The human immunodeficiency virus therapeutics market covered in this report is segmented –

1) By Drug Type: Branded Drugs, Generic Drugs

2) By Drug Class: Nucleoside-Analog Reverse Transcriptase Inhibitors (Nrtis), Non-Nucleoside Reverse Transcriptase Inhibitors (Nnrtis), Entry And Fusion Inhibitors, Protease Inhibitors (Pis), Integrase Inhibitors, Coreceptor Antagonists

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

4) By End-user: Hospitals And Clinics, Specialty Centers

Subsegments:

1) By Branded Drugs: Biktarvy, Triumeq, Genvoya, Juluca, Dovato, Isentress, Prezista

2) By Generic Drugs: Tenofovir Disoproxil Fumarate (TDF), Lamivudine, Efavirenz, Zidovudine, Nevirapine, Abacavir, Ritonavir

What are the Emerging Market Trends Driving the Growth of the Human Immunodeficiency Virus Therapeutics Industry?

Prominent corporations in the HIV therapeutics market are concentrating on developing groundbreaking treatments such as combination therapy to enhance treatment effectiveness, counter drug resistance, and increase patient compliance. Combination therapy is a strategy that combines two or more therapeutic components, like drugs or other treatments, to manage a single ailment or condition. This technique boosts the potency of the treatment, reduces side effects, and decreases the chance of drug resistance. For instance, Gilead Sciences Inc, a US biopharmaceutical firm, got the green light from the FDA in December 2022 for Sunlenca (lenacapavir), a medication used in combination with other antiretroviral drugs, targeted toward adults with multi-drug-resistant HIV-1. Sunlenca stands out as the first and the sole HIV treatment that uses a capsid inhibitor, offering biannual dosing for patients who have undergone extensive treatment. The authorization is backed up by the findings of the CAPELLA trial, which exhibited high rates of sustained virologic suppression. Sunlenca, with its novel mode of action and extended-release formulation, is projected to play an essential role in the advancement of HIV treatment and prevention tactics in the future.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/human-immunodeficiency-virus-therapeutics-global-market-report

Which Regions Are Driving Growth in the Human Immunodeficiency Virus Therapeutics Market?

North America was the largest region in the human immunodeficiency virus therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human immunodeficiency virus therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23419

This Report Delivers Insight On:

1. How big is the human immunodeficiency virus therapeutics market, and how is it changing globally?

2. Who are the major companies in the human immunodeficiency virus therapeutics market, and how are they performing?

3. What are the key opportunities and risks in the human immunodeficiency virus therapeutics market right now?

4. Which products or customer segments are growing the most in the human immunodeficiency virus therapeutics market?

5. What factors are helping or slowing down the growth of the human immunodeficiency virus therapeutics market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model